ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series
07 8월 2023 - 9:32PM
Business Wire
Presentations and live Q&A to take place on
Monday, August 14 and Wednesday, August 16
ChromaDex Corp. (NASDAQ:CDXC), a global authority on
Nicotinamide Adenine Dinucleotide (NAD+) research and healthy
aging, announced today that they will be participating in Renmark
Financial Communications Inc.’s live Virtual Non-Deal Roadshow
Series to discuss its latest investor presentation on Monday,
August 14, 2023, at 12:00 p.m. ET (9:00 a.m. PT) and Wednesday,
August 16, 2023 at 2:00 p.m. ET (11:00 a.m. PT). ChromaDex welcomes
stakeholders, investors, and other individual followers to register
and attend these live events.
The presentations will feature Rob Fried, Chief Executive
Officer, and Brianna Gerber, Chief Financial Officer. Topics to be
covered will include the latest investor presentation followed by a
live Q&A. Investors interested in participating in either of
these events will need to register using the links below. As a
reminder, registration for the live events may be limited but
access to the replay after the events will be on the company’s
Investor website. Investors may submit questions during the
presentations or may email questions to
InvestorRelations@ChromaDex.com or jkautz@renmarkfinancial.com
ahead of the event.
REGISTER HERE:
Monday, August 14, 2023:
https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-cdxc-2023-08-14-120000
Wednesday, August 16, 2023:
https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-cdxc-2023-08-16-140000
- To ensure smooth connectivity, please access this link using
the latest version of Google Chrome.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230807189001/en/
ChromaDex Media Contact: Kendall Knysch, Director of
Media Relations 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: +1 (949) 356-1620
InvestorRelations@ChromaDex.com
Renmark Financial Communications Inc. James R. Kautz:
jkautz@renmarkfinancial.com Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com
ChromaDex (NASDAQ:CDXC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
ChromaDex (NASDAQ:CDXC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024